Select a medication above to begin.
Erbitux
cetuximab
Black Box Warnings .
Infusion Rxns
3% incidence of severe infusion rxn, rarely fatal (<1 in 1000); immediately and permanently D/C tx for serious rxns
Cardiopulmonary Arrest
2% incidence of cardiopulmonary arrest and/or sudden death in head/neck squamous cell CA pts receiving cetuximab and radiation tx; 3% incidence in pts receiving cetuximab w/ platinum-based tx and 5-FU; closely monitor electrolytes incl. Mg, K, and Ca during/after tx
Adult Dosing .
Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
colorectal CA
- [EGFR-expressing metastatic dz, first-line tx]
- Dose: 250 mg/m^2/dose IV qwk, starting wk 2; Start: 400 mg/m^2/dose IV x1 on wk 1; Alt: 500 mg/m^2/dose IV q2wk; Info: for pts w/ KRAS wild-type dz; use w/ FOLFIRI as part of multi-drug chemo regimen
- [EGFR-expressing metastatic dz, previously treated]
- Dose: 250 mg/m^2/dose IV qwk, starting wk 2; Start: 400 mg/m^2/dose IV x1 on wk 1; Alt: 500 mg/m^2/dose IV q2wk; Info: for pts w/ KRAS wild-type dz; use w/ irinotecan for irinotecan-refractory dz or use as monotherapy in pts who have failed oxaliplatin- and irinotecan-based tx
- [BRAF V600E-mutated metastatic dz, previously treated]
- Dose: 250 mg/m^2/dose IV qwk, starting wk 2; Start: 400 mg/m^2/dose IV x1 on wk 1; Info: use w/ encorafenib
- [KRAS G12C-mutated locally advanced or metastatic dz (off-label)]
- Dose: 250 mg/m^2/dose IV qwk, starting wk 2; Start: 400 mg/m^2/dose IV x1 on wk 1; Alt: 500 mg/m^2/dose IV q2wk; Info: for pts who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based tx; use w/ adagrasib
squamous cell head/neck CA
- [locally or regionally advanced dz, first-line tx, combo w/ XRT]
- Dose: 400 mg/m^2/dose IV x1 at 1wk prior to XRT, then 250 mg/m^2/dose IV qwk x6-7wk during XRT
- [recurrent locoregional or metastatic dz, first-line tx, combo tx]
- Dose: 250 mg/m^2/dose IV qwk, starting wk 2; Start: 400 mg/m^2/dose IV x1 on wk 1; Alt: 500 mg/m^2/dose IV q2wk; Info: use w/ platinum-based tx w/ fluorouracil
- [recurrent or metastatic dz, monotherapy]
- Dose: 250 mg/m^2/dose IV qwk, starting wk 2; Start: 400 mg/m^2/dose IV x1 on wk 1; Alt: 500 mg/m^2/dose IV q2wk; Info: for pts w/ platinum-refractory dz
renal dosing
- [see below]
- renal impairment: no adjustment
- HD: no adjustment; no supplement; PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.